DiagnaMed Advances Hydrogen Energy Technology Innovation
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) announces progress in commercializing its proprietary electromagnetic heating technology for hydrogen production. The technology, developed by Dr. Qingwang Yuan at Texas Tech University, enables direct hydrogen extraction from petroleum reservoirs and natural hydrogen fields.
The company is integrating this newly licensed technology into existing production systems to improve efficiency and cost-effectiveness. DiagnaMed has strengthened its partnership with Québec Innovative Materials Corp. (QIMC) to expand renewable energy applications.
DiagnaMed aims to repurpose over 25,000 active oil and gas fields and 2-3 million abandoned wells in the United States for hydrogen extraction. The company is currently in discussions with petroleum and natural hydrogen exploration companies for potential partnerships.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) annuncia progressi nella commercializzazione della sua tecnologia proprietaria di riscaldamento elettromagnetico per la produzione di idrogeno. Questa tecnologia, sviluppata dal Dr. Qingwang Yuan presso la Texas Tech University, consente l'estrazione diretta di idrogeno da giacimenti petroliferi e campi di idrogeno naturale.
L'azienda sta integrando questa nuova tecnologia concessa in licenza nei sistemi di produzione esistenti per migliorare l'efficienza e la convenienza economica. DiagnaMed ha rafforzato la sua partnership con Québec Innovative Materials Corp. (QIMC) per ampliare le applicazioni delle energie rinnovabili.
DiagnaMed mira a riutilizzare oltre 25.000 giacimenti attivi di petrolio e gas e 2-3 milioni di pozzi abbandonati negli Stati Uniti per l'estrazione di idrogeno. L'azienda è attualmente in discussione con compagnie di esplorazione petrolifera e di idrogeno naturale per potenziali collaborazioni.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) anuncia avances en la comercialización de su tecnología de calefacción electromagnética para la producción de hidrógeno. La tecnología, desarrollada por el Dr. Qingwang Yuan en la Texas Tech University, permite la extracción directa de hidrógeno de reservorios de petróleo y campos de hidrógeno natural.
La empresa está integrando esta nueva tecnología licenciada en los sistemas de producción existentes para mejorar la eficiencia y la rentabilidad. DiagnaMed ha fortalecido su asociación con Québec Innovative Materials Corp. (QIMC) para expandir las aplicaciones de energía renovable.
DiagnaMed tiene como objetivo reutilizar más de 25,000 campos activos de petróleo y gas y de 2 a 3 millones de pozos abandonados en los Estados Unidos para la extracción de hidrógeno. La empresa está actualmente en conversaciones con compañías de exploración de petróleo e hidrógeno natural para posibles asociaciones.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF)는 수소 생산을 위한 독점적인 전자기 가열 기술 상용화의 진전을 발표했습니다. 이 기술은 텍사스 공대의 Dr. Qingwang Yuan이 개발하였으며, 석유 저수지와 자연 수소 필드에서 수소를 직접 추출할 수 있게 해줍니다.
회사는 효율성과 비용 효과성을 개선하기 위해 이 새로 라이센스된 기술을 기존 생산 시스템에 통합하고 있습니다. DiagnaMed는 Québec Innovative Materials Corp. (QIMC)와의 파트너십을 강화하여 재생 가능 에너지 응용 프로그램을 확장하고 있습니다.
DiagnaMed는 수소 추출을 위해 미국 내 25,000개 이상의 활성 석유 및 가스 필드와 200만~300만 개의 폐기된 우물을 재활용할 계획입니다. 현재 회사는 잠재적인 파트너십을 위해 석유 및 자연 수소 탐사 회사와 논의 중입니다.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) annonce des avancées dans la commercialisation de sa technologie de chauffage électromagnétique propriétaire pour la production d'hydrogène. La technologie, développée par le Dr Qingwang Yuan à la Texas Tech University, permet l'extraction directe d'hydrogène à partir de réservoirs de pétrole et de champs d'hydrogène naturel.
L'entreprise intègre cette nouvelle technologie sous licence dans les systèmes de production existants afin d'améliorer l'efficacité et la rentabilité. DiagnaMed a renforcé son partenariat avec Québec Innovative Materials Corp. (QIMC) pour élargir les applications des énergies renouvelables.
DiagnaMed vise à réutiliser plus de 25 000 champs pétroliers et gaziers actifs et 2 à 3 millions de puits abandonnés aux États-Unis pour l'extraction d'hydrogène. L'entreprise est actuellement en discussion avec des sociétés d'exploration pétrolière et d'hydrogène naturel pour d'éventuels partenariats.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) gibt Fortschritte bei der Kommerzialisierung seiner proprietären elektromagnetischen Heiztechnologie zur Wasserstoffproduktion bekannt. Die Technologie, die von Dr. Qingwang Yuan an der Texas Tech University entwickelt wurde, ermöglicht die direkte Wasserstoffextraktion aus Erdölreservoirs und natürlichen Wasserstofffeldern.
Das Unternehmen integriert diese neu lizenzierte Technologie in bestehende Produktionssysteme, um die Effizienz und Kosteneffektivität zu verbessern. DiagnaMed hat seine Partnerschaft mit Québec Innovative Materials Corp. (QIMC) gestärkt, um die Anwendungen erneuerbarer Energien auszubauen.
DiagnaMed plant, über 25.000 aktive Öl- und Gasfelder sowie 2-3 Millionen stillgelegte Brunnen in den Vereinigten Staaten zur Wasserstoffextraktion umzuwandeln. Das Unternehmen befindet sich derzeit in Gesprächen mit Erdöl- und natürlichen Wasserstoffexplorationsunternehmen über potenzielle Partnerschaften.
- Licensed new electromagnetic heating technology for hydrogen production from Texas Tech University
- Strategic partnership with Québec Innovative Materials Corp. for technology implementation
- Access to substantial infrastructure: 25,000+ active oil fields and 2-3M abandoned wells in the US
- No current revenue generation from the technology
- Technology still in development phase, not yet commercially proven
- Dependent on successful partnership negotiations for implementation
TORONTO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed”, “DMED”, or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a leading provider of cutting-edge technology solutions for the hydrogen and life sciences industries, is pleased to announce significant progress in the commercialization of its proprietary electromagnetic heating technology for hydrogen production. Developed by Dr. Qingwang Yuan of the HOPE Group at Texas Tech University, this groundbreaking innovation enables the direct extraction of hydrogen from petroleum reservoirs and natural hydrogen fields, positioning DiagnaMed at the forefront of sustainable energy solutions.
Key Developments:
Advanced Technology Integration. DiagnaMed is integrating the newly licensed, state-of-the-art hydrogen generation technology from Texas Tech into its existing production systems. This enhancement is expected to drive increased efficiency, scalability, and cost-effectiveness in hydrogen production.
Strengthened Partnership with Québec Innovative Materials Corp. The long-standing alliance between DMED and QIMC is being bolstered through initiatives that leverage DMED’s enhanced hydrogen technology capabilities and QIMC’s industry-leading expertise in natural hydrogen. Together, the partners are positioned to expand renewable energy applications and accelerate the adoption of clean energy.
Commitment to Sustainability. DMED and QIMC remain dedicated to reducing greenhouse gas emissions and advancing the global shift to low-carbon energy. Their expanded collaboration reinforces a shared commitment to developing economically viable, environmentally responsible energy solutions.
Advancing Business Development and Partnering Discussions. DMED is committed to empowering the energy sector through repurposing existing oil and gas infrastructure, including over 25,000 active oil and gas fields and the 2-3 million abandoned wells in the United States, and accelerating the extraction of natural clean hydrogen from geologic hydrogen properties. DMED is in partnering discussions with petroleum and natural hydrogen exploration companies.
Fabio Chianelli, Chairman and CEO of DiagnaMed, commented:
“We are focused on commercializing our unique hydrogen production technology through strategic alliances with energy innovators, enabling cost-effective, carbon-neutral hydrogen production that aligns with global sustainability goals. We expect to engage with petroleum and natural hydrogen exploration companies that will further validate our business proposition and drive revenue at scale.”
About DiagnaMed
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) delivers innovative technology solutions for the cleantech and life sciences industries, with a focus on hydrogen production and AI-driven drug discovery and diagnostics. Visit DiagnaMed.com.
For more information, please contact:
Fabio Chianelli
Chairman and CEO
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “will”, “may”, “expect”, “could”, “can”, “estimate”, “anticipate”, “intend”, “believe”, “projected”, “aims”, and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the year ended September 30, 2024 (“MD&A”), dated January 28, 2025, which is available on the Company's profile at www.sedarplus.ca. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.
FAQ
What is DiagnaMed's (DGNMF) new hydrogen production technology?
How many potential oil and gas sites can DGNMF utilize for hydrogen extraction in the US?
What is the partnership between DGNMF and Québec Innovative Materials Corp?
What are the commercial prospects for DGNMF's hydrogen technology in 2025?
